Open [Tokyo, Japan] Study of the Efficacy and Safety for Rituximab in Myalgia Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

[Utsikt]

But what if it reports positive results?!

I think it's worth a philosophical discussion about how to manage that.

Wouldn’t that depend on what the actual results are and what kind of data we get access to?